Here is What a KOL Had to Say About Selecta
Insights - On Thursday, March 8th, 2018 SlingShot Insights hosted a KOL call with Dr.Vibeke Strand, discussing Selecta (SELB) and the current treatments for gout. Below are … Continue Reading
PremiumAuthor Archives: D Mero
GBT’s Latest Financing Could Mean Pipeline Expansion is in the Works
Insights - After market close on Thursday, Global Blood Therapeutics (GBT) announced an offering of 4M shares with a 30-day option to purchase additional 600,000 shares at $54/share. This … Continue Reading
Premium
State of Dermira Post Phase 3 Acne Failure
Insights - Dermira announced the highly anticipated data for their Phase 3 acne drug this morning. They failed. Big time. Dermira did not show statistical significance in any of their 3 … Continue Reading
Read nowEven Though Some Institutions Bailed, Selecta Promising Ahead of Data
Insights - Following the disappointing November 2017 Phase 2 data, Selecta has seen a down trend in price action. With 13-G filings (institutional ownership) trickling out for … Continue Reading
Read now
A Play on Healthcare Without The Conventional Risks
Insights - SWK Holdings (SWKH:OTCBB) is not the typical biotech company that we’ve historically covered, but it has all characteristics we look for in an investment: Trading … Continue Reading
Premium
Phase 3 Acne Data Will Make or Break Dermira
Insights - Dermira (DERM) is expected to read out pivotal Phase 3 data for their topical acne drug before the end of Q1’18. Instead of picking a … Continue Reading
Read now